United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

23 Sep 2016
Change (% chg)

$-1.62 (-2.21%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BLUE.OQ


bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and... (more)


Beta: --
Market Cap(Mil.): $2,664.34
Shares Outstanding(Mil.): 37.17
Dividend: --
Yield (%): --


  BLUE.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -5.58 -- --
ROI: -21.93 -0.26 13.91
ROE: -24.47 -3.05 14.82

BRIEF-Bluebird Bio's LentiGlobin investigational gene therapy accepted into Europen Medicines Agency's PRIME program

* LentiGlobin(TM) investigational gene therapy for transfusion-dependent beta-thalassemia accepted into European Medicines Agency's PRIME program Source text for Eikon: Further company coverage:

Sep 21 2016

BRIEF-Bluebird bio reports qtrly loss per share of $1.59

* Bluebird bio reports second quarter 2016 financial results and recent operational progress

Aug 03 2016

BRIEF-Bluebird Bio says co, Lonza Houston enter into manufacturing agreement

* Bluebird Bio Inc says Lonza Houston Inc and co have entered into a strategic manufacturing agreement

Jun 09 2016

BRIEF-Bluebird Bio reports Q1 collaboration revenue $1.5 million

* Bluebird Bio reports first quarter 2016 financial results and recent operational progress

May 04 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Provider : Reuters Investment Profile
Provider : Reuters Investment Profile
Provider : Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.